U7snRNA gene therapy to restore dystrophin for Duchenne and Becker muscular dystrophy
(Project 2) Development of U7snRNA Vectors for Dystrophinopathy
This project uses tiny genetic delivery vehicles (AAV carrying U7snRNA) to change DMD gene splicing so people with Duchenne or Becker muscular dystrophy can make working dystrophin protein.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst Nationwide Children's Hosp NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project ID | NIH-11169987 on NIH RePORTER |
What this research studies
Researchers are developing AAV-delivered U7snRNA vectors that redirect how cells splice the DMD gene so more functional dystrophin is produced. They plan to optimize vector designs for strong exon skipping, create personalized vectors for rare mutations like single exon duplications, and develop variants that apply to broader groups with common out-of-frame deletions. Work includes laboratory and mouse experiments and builds on early human data such as a reported infant Dup2 case. The team aims to achieve more robust dystrophin expression than seen with current micro-dystrophin approaches.
Who could benefit from this research
Good fit: People with Duchenne or Becker muscular dystrophy whose DMD mutations are amenable to exon skipping (for example single-exon duplications or certain out-of-frame rod-domain deletions) would be the ideal candidates.
Not a fit: Patients whose DMD mutations are not correctable by exon skipping or those with unrelated muscle disorders or very advanced muscle loss may not benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could restore near–full-length dystrophin in some patients, improving muscle function and slowing disease progression.
How similar studies have performed: Exon-skipping therapies and AAV-delivered U7snRNA have shown encouraging results in animal studies and some early patient reports, but clear clinical benefit in larger human trials has not yet been established.
Where this research is happening
Columbus, United States
- Research Inst Nationwide Children's Hosp — Columbus, United States (Active)
Researchers
- Principal investigator: Flanigan, Kevin M — Research Inst Nationwide Children's Hosp
- Study coordinator: Flanigan, Kevin M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.